Teva wins ruling over Coreg damages in US

Teva cannot be ordered to pay just over US$235 million in damages to GlaxoSmithKline (GSK) for infringing a method-of-use patent shielding the originator’s Coreg (carvedilol) antihypertensive, because “substantial evidence” does not support a federal jury’s earlier finding that Teva was liable for induced infringement through sales of its generic, a US district court has ordered.